Tri-Heal (TB-500 + BPC-157 + KPV blend)
Also called Tri-Heal blend
A research blend that combines TB-500, BPC-157 and KPV. Each ingredient has its own early research, but the combination itself has not been tested in a controlled human trial.
Overview
What it is
One supplier lists its 45 mg vial as 25 mg TB-500, 10 mg BPC-157 and 10 mg KPV. The total mass is not 45 mg of each ingredient, and the label describes vial contents only.
How it works
BPC-157 increased growth-hormone receptor expression in tendon cells in a lab study. Full-length thymosin beta-4 improved skin-wound repair in rats, though TB-500 is a fragment and results do not automatically transfer. KPV reduced inflammation in two mouse colitis models when given by mouth.
What the research shows
No controlled human study of the three-ingredient combination was identified, so claims of "synergy" remain unproven. Each ingredient's evidence comes from different routes, tissues and disease models.
Studied for
- Tendon cell behaviorBPC-157, lab
- Skin wound repairthymosin beta-4, rats
- Intestinal inflammationKPV, mice
Safety and regulatory status
Safety and side effects
No dependable human side-effect rate exists for the blend. The FDA has noted limited safety information for KPV and safety concerns involving BPC-157 and the thymosin beta-4 fragment. Combining ingredients also makes it harder to tell what caused a reaction.
Regulatory status
Not FDA approved. FDA lists BPC-157 and the TB-500-related fragment among compounding substances with potential safety risks.
Mixing and dosing reference
Reference information only. Read before using this section.
Tri-Heal (45 mg Blend) Dosage Protocol
- Vial
- 45 mg total blend 25 mg TB-500 + 10 mg BPC-157 + 10 mg KPV
- Add diluent
- 3 mL
- Concentration
- 15 mg/mL
- 1 unit (U-100)
- 150 mcg total in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous).
- Typical range
- 500–2000 mcg once daily (gradual titration over 8 weeks).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard 8-Week Protocol
| Week | Daily Dose | U-100 Units (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 3.3 units (0.033 mL)* |
| Weeks 3–4 | 1000 mcg (1.0 mg) | 6.7 units (0.067 mL)* |
| Weeks 5–6 | 1500 mcg (1.5 mg) | 10 units (0.10 mL) |
| Weeks 7–8 | 2000 mcg (2.0 mg) | 13.3 units (0.133 mL) |
Extended 12-Week Protocol
| Week | Daily Dose | U-100 Units (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 3.3 units (0.033 mL)* |
| Weeks 3–4 | 1000 mcg (1.0 mg) | 6.7 units (0.067 mL)* |
| Weeks 5–6 | 1500 mcg (1.5 mg) | 10 units (0.10 mL) |
| Weeks 7–8 | 2000 mcg (2.0 mg) | 13.3 units (0.133 mL) |
| Weeks 9–10 | 2500 mcg (2.5 mg) | 16.7 units (0.167 mL) |
| Weeks 11–12 | 3000 mcg (3.0 mg) | 20 units (0.20 mL) |
Extended 16-Week Protocol
| Week | Daily Dose | U-100 Units (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 3.3 units (0.033 mL)* |
| Weeks 3–4 | 1000 mcg (1.0 mg) | 6.7 units (0.067 mL)* |
| Weeks 5–6 | 1500 mcg (1.5 mg) | 10 units (0.10 mL) |
| Weeks 7–8 | 2000 mcg (2.0 mg) | 13.3 units (0.133 mL) |
| Weeks 9–10 | 2500 mcg (2.5 mg) | 16.7 units (0.167 mL) |
| Weeks 11–12 | 3000 mcg (3.0 mg) | 20 units (0.20 mL) |
| Weeks 13–14 | 3500 mcg (3.5 mg) | 23.3 units (0.233 mL) |
| Weeks 15–16 | 4000 mcg (4.0 mg) | 26.7 units (0.267 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto the lyophilized cake.
- Gently swirl or roll until fully dissolved (do not shake vigorously).
- Label with date and concentration (15 mg/mL); refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 500 mcg daily; increase by 500 mcg every 2 weeks as tolerated.
- Target: 1500–2000 mcg daily by Weeks 5–8 (standard); up to 3000–4000 mcg for extended protocols.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites systematically.
Storage
- Lyophilized: Follow the exact product’s labeled storage temperature and expiration instructions; keep the vial dry and protected from light.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow formulation-specific use-by and sterile-handling instructions. Do not assume aliquoting extends stability or sterility; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry completely before proceeding.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation.
- Dispose of used syringes in an approved sharps container; never recap or reuse needles.
Important notes
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose, site rotation, and any observations to maintain consistency.
- For doses under 10 units, use 30-unit or 50-unit insulin syringes for improved accuracy.
Protocol source: PeptideDosages.com
Common questions
Is Tri-Heal a single peptide?
No. It is a three-ingredient blend.
Does the KPV make it a proven gut treatment?
No. Mouse findings with oral KPV do not establish benefit from an injectable human combination.
Does a certificate of analysis prove it is safe?
No. Purity testing confirms what is in the vial; it does not show clinical safety or benefit.
Related in Performance and Recovery
Sources and further reading (5)
- Chang CH, et al. BPC-157 and growth-hormone receptor expression in tendon fibroblasts, 2014.
- Malinda KM, et al. Thymosin beta-4 and experimental wound healing, 1999.
- FDA. Compounding substances with potential significant safety risks.
- Dalmasso G, et al. PepT1-mediated KPV uptake and intestinal inflammation. Gastroenterology, 2008.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Laboratory research material: TB10 + BPC10 + KPV Research Use Only